Search Follow us


aap Implantate’s preliminary FY17 results show an encouraging 20% y-o-y growth in trauma revenues, with the strongest performance coming from the North American distribution business. Management has guided to continued revenue growth and reducing EBITDA losses in FY18. Delivery on key partnerships and the commercialisation of the silver-coating technology are the main stepping points to eventual profitability. The near-term goal for aap is to start the human clinical trial for the silver-coating technology with the aim of reaching CE and FDA approval.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs